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Background: Hepatocyte Growth Factor (HGF) enhances cytotoxicity of paclitaxel (PTX) and cisplatin (CDDP) in
human ovarian cancer cells. Because of potential pitfalls of HGF exogenous administration, we investigated whether
HGF serum concentration might be alternatively raised in vivo by administering low molecular weight heparin
(LMWH).
Methods: The main HGF pharmacokinetic parameters were evaluated following acute and chronic LMWH
treatment. First, women, operated on for gynaecological tumors, were treated with a single dose of calcium
nadroparin and studied for 12 hours. Next, women operated on for benign or malignant gynaecological tumors
were treated daily with calcic nadroparin for one month. Subsequently, the biological activity of the measured HGF
serum levels was tested in assays of ovarian cancer cell sensitization to drugs.
Results: In the short-term treated group, median HGF AUCss, Cmax and Caverage were about four-fold that of the
control group, whereas Cmin was three-fold. In the patients treated chronically median HGF serum levels rose about
six-fold in the first week, and decreased but remained significantly higher after one month. The pharmacokinetic of
nadroparin-dependent HGF increase were similar in the two groups. The HGF concentrations measured after both
acute and chronic treatment were found to be effective in sensitising ovarian cancer cells to chemotherapeutics.
Conclusions: This study raises the possibility of using LMWH to increase HGF serum concentration and to take
advantage of its biological activities. In particular, nadroparin might be used as a chemo-potentiating agent in
epithelial cell ovarian carcinoma through its action on HGF serum concentration.
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The biological activities of Hepatocyte Growth Factor have
been thoroughly investigated both in vitro and in vivo.
HGF is implicated in epithelial–to-mesenchymal transition,
thus promoting migration, invasion and motility of several
cellular types [1]. It promotes blood vessel formation [2]
and directs the orderly and homogenous proliferation and
organisation of cellular types during embryogenesis, organ
regeneration and wound healing [3]. These HGF activities
have led to think about therapeutic applications of HGF
administration. This growth factor could play a significant
role in hepatic regeneration after acute and chronic liver
injuries [4-6]. Similarly, HGF could be used to facilitate
and accelerate regeneration after acute and chronic renal
injury [7,8]. After an acute myocardial infarction, HGF
shows a cardio-protective action [9].
Several studies have also pointed out the importance
of the paracrine action of HGF on neoplastic transform-
ation in several tumor types, such as in the Epithelial
Cell Ovarian Carcinoma (ECOC) [10]. The intracellular
signalling pathway involving the HGF receptor encoded
by the MET oncogene is implicated in cell “invasive
growth” [11,12] and the MET oncogene has been found
activated in human cancer by over-expression with or
without gene amplification, point mutation and auto-
crine circuit (see at http://www.vai.org/met/). In line
with these findings, inhibitors of the HGF-MET axis
have been proposed for cancer treatments and are pres-
ently undergoing clinical trials. In a preclinical model of
ovarian cancer, an orally available small-molecule inhibi-
tor of c-Met, PF-2341066, has been reported to reduce
tumour burden and metastasis [13].
However, in 2004, Rasola A. et al. unexpectedly
revealed that pre-treatment with HGF enhances the
apoptotic response of human ovarian cancer cells to very
low doses of paclitaxel (PTX) and cisplatin (CDDP) [14].
Through its receptor and the p38 mitogen-activated kin-
ase (MAPK) pathway [15], HGF acts on the intrinsic
pathway activated by the chemotherapeutics in a dose
dependent manner. The same research group obtained
similar results in a preclinical model into immunocom-
promised mice [16]: they found a therapeutic window
wherein HGF, with a paracrine/autocrine action, sensi-
tises tumours to low doses of CDDP and PTX, which
are otherwise ineffective. In this way, they demonstrated
that the HGF-mediated enhancement of apoptosis
induced by PTX and CDDP lasts even if the cells are
exposed to it in a continuous manner.
Following these results, we investigated how the HGF
concentration might be raised in vivo. Although, at least
hypothetically, it could be possible to use gene therapy or
to administer human recombinant HGF (hrHGF), the lat-
ter therapies are not standardised and require appropriate
studies. We consider an alternative way of raising HGFserum concentration by administering low molecular
weight heparin (LMWH) as suggested by preliminary data
in the literature [17-19], taking advantage by the fact that
heparin is often necessary during the treatment of cancer
patients. In the present paper, HGF pharmacokinetic para-
meters are explored after nadroparin administration in a
population of gynaecological patients affected by benign
and malignant diseases. We then test HGF effectiveness in
sensitising ovarian cancer cell lines to chemotherapeutics
at the plasma concentrations obtained in patients follow-
ing nadroparin administration.Methods
Study protocol
The study consisted of two phases. In the first phase, the
main HGF pharmacokinetic parameters were evaluated,
comparing a group of six women treated with a single
dose of calcic nadroparin to a control group of six un-
treated women. Venous blood was drawn in both groups
at 0, 30, 60, 90, 120, 150, 180, 240, 300, 360, 480 and
720 min. In the second phase, the HGF basal and max-
imum concentrations were measured in 17 women,
undergoing one month of calcic nadroparin daily treat-
ment. Venous blood was drawn twice on day 1 (at 0 and
90 min after nadroparin administration), then once on
days 8 and 28 (at 90 min after LMWH injection). Calcic
nadroparin was given subcutaneously at 2850 IU/0.3 ml
anti-Xa (FraxiparinaW, GSK Italy).Patients’ characteristics
In the first phase, 12 patients were enrolled, 6 treated
with nadroparin for prophylactic anticoagulation and an-
other 6 untreated as the control group. The six
nadroparin-group patients were affected by benign pelvic
gynaecologic diseases: three requiring laparoscopy and
three laparotomy. All of them were treated at the Gynae-
cological Oncology Unit of the hospital Azienda Sani-
taria Ospedaliera Ordine Mauriziano in Turin, Italy.
Their median age was 42 years (range 35–52), and their
median BMI was 22.8 kg/m2. In the control group, four
were healthy women volunteers and two patients sub-
mitted to gynaecological pelvic surgery, but these
women were not treated with prophylactic LMWH.
Their median age was 30 years (range 25–60), and their
median BMI was 19.1 kg/m2.
In the second phase, 17 patients were enrolled among
women planning gynaecological pelvic surgery and treated
for 4 weeks with nadroparin for prophylactic anticoagula-
tion. All these patients underwent laparotomy; ten were
affected by malignancy (ECOC) and seven by benign
(uterine fibroma, ovarian cystadenoma) pelvic gynaecolo-
gic diseases. Their median age was 53 years (range 41–
75 years), and their median BMI was 22.1 kg/m2.
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Inclusion criteria for phase 1 were as follows: age≥18 years,
ECOG Performance Status≤1; neutrophils≥1500 μl-1,
platelets≥150000 μl-1, creatinine 0.6-1.2 mg/dl, total
bilirubin≤1 mg/dl, AST≤35 IU/l, and ALT≤45 IU/l.
Inclusion criteria for phase 2 were the same as for phase
one, together with moderate-high risk of deep venous
thrombosis (DVT), anticipated anaesthesia > 30 min, obes-
ity, varicose veins, previous DVT and/or pulmonary em-
bolism, thrombophilia, prolonged immobility, and
congestive heart failure.
General exclusion criteria were as follows: serious liver
or renal diseases, diabetes, hyperlipidemia, serious osteo-
porosis, pregnancy or lactation, high risk of bleeding
(hemorrhagic diathesis, peptic ulcer), inflammatory or
infectious diseases, previous cancer, consumption of cof-
fee, tobacco or ethanol in the last 24 hours, and women
in treatment with immunosuppressive drugs, contracep-
tives, lipid lowering agents, or antiaggregants.
All patients and healthy volunteers gave written informed
consent prior to enrolment into the study, which was
approved by the local ethics committee (CE Interaziendale
AO San Giovanni Battista – OIRM Sant’Anna, Torino).
Reagents and cell line
Cisplatin (CDDP) was from Bristol-Myers Squibb (Rocky
Hill, NJ); APC conjugated Annexin V was from Boehrin-
ger Mannheim (Indianapolis, IN) and tetramethylrhoda-
mine methyl ester (TMRM) was from Molecular Probes
(Eugene, OR); all of the other chemicals were from
Sigma (St. Louis, MO). Pure human recombinant HGF
was from R&D Systems (Minneapolis, MN). SK-OV-3 cells
were purchased from American Type Culture Collection
(Manassas, VA) and grown as suggested by the provider.
HGF determination
The ELISA kit for the determination of HGF in patients’
serum was purchased from BioSource (Camarillo, USA).
Blood samples were collected using BD VacutainerW
tubes without additives, blood for serum preparation
was left to coagulate and then centrifuged at 3000 rpm
for 10 minutes. All samples were coded, stored at −65°C
and analysed within 2 months.
Apoptosis assay
Apoptosis assay was used to evaluate if the HGF concen-
trations measured in patients after nadroparin adminis-
tration were effective in sensitising ovarian cancer cells
to CDDP. SK-OV-3 ovarian cancer cells were pre-
treated with decreasing concentrations of recombinant
HGF and, after 48 hours, exposed to medium supple-
mented with 20 μM CDDP to induce apoptosis. We then
measured the percentage of live cells, i.e. cells that did
not display either early or late apoptotic features. Flowcytometry recordings of several independent apoptotic
changes were performed by a single-tube analysis as pre-
viously described (Rasola A. et al., 2004). Briefly, after
treatment, cells were resuspended in HEPES buffer
(10 mM HEPES, 135 mM NaCl, and 5 mM CaCl2) and
incubated for 60 min at 4°C in APC-conjugated
Annexin V, TMRM (200 nM), and propidium iodide
(PI; 1 μg/ml) to detect phosphatidylserine exposure on
the cell surface, mitochondrial inner membrane electro-
chemical gradient, and plasma membrane integrity,
respectively. Cell morphology changes were analysed
following variations of the forward and side light scatter.
Samples were acquired on a CyAn flow cytometer and
analysed with Summit V4.3 software (Dako Colorado, Inc).
Pharmacokinetic Analysis
The pharmacokinetic study entailed a typical model-free
approach, the non-compartmental analysis (NCA). The
goal of NCA is to provide an estimate of the main phar-
macokinetic parameters by the trapezoidal rule, the only
assumption being that the terminal elimination phase
can be described by a mono-exponential equation, fol-
lowing first order kinetics. NCA was performed using
Kinetica 2000 4.1.1 (InnaPhase Corp., USA), estimating
the following HGF parameters: Cmax (maximum concen-
tration), Cmin (minimum concentration), Caverage (aver-
age concentration at steady state), Tmax (time to reach
maximum concentration) and AUCss (area under con-
centration/time curve at steady state).
Statistical Analysis
HGF pharmacokinetic parameters were compared dur-
ing phase 1 (control vs. nadroparin group), phase 1 vs. 2
(nadroparin group) and phase 2 (nadroparin group, be-
nign vs. malignant tumours) by the Mann–Whitney test,
while the four HGF levels during phase 2 were com-
pared by repeated measures analysis of variance plus
within-subjects contrasts. All reported p values were
obtained by two-sided exact method, at the conventional
5% significance level. Data were analysed as of March
2009 by SPSS 17.0 (SPSS Inc., USA). All data are pre-
sented as median values and range.
Results
The effect of a single nadroparin administration on
HGF serum levels was investigated during phase 1
(control vs. nadroparin group); two different HGF kin-
etics profiles can be recognised at a glance, corresponding
to control untreated women and LMWH-treated patients
(Figure 1).
Table 1 summarises the main HGF pharmacokinetic
parameters, comparing the two phase 1 groups by
Mann–Whitney test.
Figure 1 HGF concentration/time curve in phase 1 (controls: 2-5-6-8-10-12; nadroparin: 1-3-4-7-9-11).
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Caverage were about four-fold that of the control group,
while Cmin is threefold; at the same time, HGF Tmax was
strongly reduced from about 6 to 1.5 hours, after pre-
treatment with nadroparin. Data show that nadroparin
was able to notably increase HGF serum levels (Cmax from
1.58 to 6.41 ng/ml), affecting its kinetic behaviour and
steady state profile (AUCss from 534 to 2157 ng*min/ml).The median Tmax in LMWH group (93 min) can be used
as a reference in phase 2 to verify if the HGF concentra-
tion’s increase after a single LMWH administration per-
sists even after a month of daily repeated treatment with
nadroparin.
The 17 patients taking part in phase 2 (nadroparin
group, benign vs. malignant tumours) were all treated
with daily nadroparin for 1 month. Median HGF serum
Table 2 Median (range) HGF Cmax in phase 1 vs. phase 2,
nadroparin group
HGF phase 1 vs. HGF phase 2 HGF phase 1 HGF phase 2 p
Cmax (ng/ml) 6.41 (0.75-7.38) 4.59 (2.75-6.25) 0.060
Table 1 Median (range) HGF parameters during phase 1,
control vs. nadroparin group
HGF phase_1 control nadroparin p
Cmax (ng/ml) 1.58 (0.80-5.65) 6.41 (0.75-7.38) 0.087
Cmin (ng/ml) 0.60 (0.33-1.20) 1.76 (0.35-3.60) 0.037
Caverage (ng/ml) 0.74 (0.47-2.38) 2.99 (0.34-4.08) 0.065
Tmax (min) 367 (30–500) 93 (30–122) 0.043
AUCss (ng*min/ml) 534 (340–1714) 2157 (243–2938) 0.065
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LMWH administration) to 4.59 ng/ml (Cmax at day 0,
90 min after LMWH administration). Median HGF Cmax
was almost constant at day 8 (4.19 ng/ml) after the first
week of LMWH treatment, whereas at day 28, levels
decreased to 2.96 ng/ml; this trend is represented in
Figure 2.
From testing HGF Cmax in phase 1 vs. 2 (both
obtained after a single nadroparin administration), the
effect on HGF maximum concentrations seems to be
minor, even if the statistical significance is borderline
(Table 2). In the last period of phase 2 and after 4 weeks
of daily LMWH treatment, HGF concentration slightly
decreased.
Basal HGF levels before nadroparin administration
(HGF_pre) and HGF Cmax concentrations after the first
nadroparin administration (HGF post_1), after 8 and
28 days of treatment (HGF post_2 and HGF post_3) are
represented in Table 3.
Analysing the phase 2 HGF concentrations, it is pos-
sible to confirm the HGF pharmacokinetic nadroparin-
dependent alteration, already found in phase 1. Using a
repeated measures analysis of variance model, the HGF
four sequential levels differ from one another (p < 0.001).
Applying then the within-subjects contrasts techniqueFigure 2 Median HGF concentration during phase 2,
nadroparin group.enables us to compare the possible couples of phase 2
HGF serum levels. There was a strong, statistically sig-
nificant difference (p < 0.001) among HGF_pre basal
concentrations and any of the three HGF concentrations
during nadroparin therapy. The decrease between
HGF_post1 and HGF_post2 was moderate (−0.40 ng/ml,
p = 0.449), while between HGF_post2 and HGF_post3
was about 30% (−1.23 ng/ml, p = 0.029).
We compared the same previous phase 2 HGF con-
centrations by stratifying them by the nature of onco-
logical disease in the 17 patients, 10 malignant (ECOC)
and 7 benign (uterine fibroma, ovarian cystadenoma)
(Table 4). The only statistically significant difference was
between HGF_post2 concentrations after the first week
of daily nadroparin administration.
In three of our phase 2 patients, we measured basal
and Cmax HGF concentration at all the observational
points (the first day of heparin treatment, after a week
and after a month of daily treatment), and we found that
at all points the basal and the Cmax concentrations dif-
fered significantly (a median of 0.49 ng/ml at basal con-
centration versus a median of 3.64 ng/ml at Cmax).
Moreover, one of our phase 2 patients was previously
under treatment with nadroparin 9500 UI anti-Xa for
11 months because of an episode of deep venous
thromboembolism (VTE). In this patient, we observed an
HGF concentration increase from 1.15 ng/ml before to
3.84 ng/ml after heparin administration (data not shown).
Finally, we evaluated whether the HGF concentrations
measured in our patients after nadroparin administra-
tion were effective in sensitising ovarian cancer cells to
chemotherapeutics. Rasola A. et al. previously showed
that in vitro, a concentration as low as 25 ng/ml was ef-
fective, but lower concentrations were never tested.
Moreover, in a preclinical model, Bardella et al. (2007)
demonstrated the strong effectiveness in vivo of a local
concentration of 250 ng/ml, extremely higher than that
obtained in our patients. We therefore tested the effect-
iveness of lower decreasing concentrations of recombin-
ant HGF and found that a level as low as 1.25 ng/ml of
HGF was able to sensitise ovarian cancer cells to cis-
platin (Figure 3).
Discussion
We studied the pharmacokinetic characteristics of the
heparin-induced increase of HGF serum concentration
in an attempt to find an alternative way to raise it en-
dogenously rather exogenously. Molecular therapies with
Table 3 Median (range) HGF levels during phase 2, nadroparin group
HGF phase 2 HGF_pre HGF_post1 HGF_post2 HGF_post3 p
Cmax (ng/ml) 0.65 (0.33-1.68) 4.59 (2.75-6.25) 4.19 (1.91-6.08) 2.96 (2.08-5.64) <0.001
HGF_pre vs. HGF_post1, HGF_pre vs. HGF_post2, HGF_pre vs. HGF_post3 <0.001
HGF_post1 vs. HGF_post2 0.449
HGF_post2 vs. HGF_post3 0.029
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several diseases. Unfortunately, the exogenous adminis-
tration of HGF in most cases fails to be effective because
of several pitfalls, such as the short half life of the full-
size and biologically active HGF, lack of activity of the
more stable HGF precursor, which should be processed
into the active form, and the poor affinity of shorter
HGF analogues, which are biologically active only at
high concentrations. Alternative ways of administering
the active form have been tested, including the use of
plasmid and viral vectors, but, beside the need for stand-
ardisation, safety of the HGF therapy should be assessed.
For example, in 2005, Nakagami H. et al., showed clin-
ical improvement in 11 patients with critical limb ische-
mia after the intramuscular injection of naked plasmid
DNA of HGF, but biodistribution studies showed that
transgene expression was limited to the site of injection.
We studied the increase of HGF serum concentration
in vivo after heparin administration. Several studies
[20,21] already suggested that some of the biological ac-
tivities of heparin in vivo, such as boosting angiogenesis
and liver regeneration, could be explained by the
heparin-induced increase in HGF serum concentration.
To take clinical advantage of the HGF-induced activity,
avoiding heparin’s anticoagulant activity, it has been pro-
posed [22] the use of decasaccharides produced by the
digestion of heparin with heparinase.
Here we report that subcutaneous administration of
nadroparin causes a striking and stable increase in HGF
serum concentration. In fact, approximately 90 min after
a single administration, we obtained a concentration of
HGF five-fold that of controls. During an observationTable 4 Median (range) HGF levels in phase 2, nadroparin
group, benign vs. malignant tumours
HGF phase_2 Cmax (ng/ml) p
HGF_pre benign 0.58 (0.38-1.68) 0.584
HGF_pre malignant 0.40 (0.33-1.03)
HGF_post1 benign 3.70 (2.76-6.19) 0.155
HGF_post1 malignant 4.98 (3.15-6.25)
HGF_post2 benign 3.18 (1.91-5.73) 0.030
HGF_post2 malignant 5.35 (4.20-6.08)
HGF_post3 benign 2.96 (2.43-5.64) 0.867
HGF_post3 malignant 2.78 (2.08-4.08)time of 12 hours in treated patients, we found an HGF
Caverage four-fold higher than in controls; the elevation
in HGF serum concentration reaches a peak after one
hour and then decreases progressively, returning to a
basal level at about 12 hours after LMWH injection. In
the second phase of our study, we measured the HGF
serum concentration in patients treated for one month
with LMWH, and we found that even at the end of the
observations, the elevation in HGF concentration was
four-fold higher than before nadroparin injection. In one
case, we also measured serum HGF eleven months after
daily administration of LMWH because of an episode of
deep venous thromboembolism, and we observed that
the HGF concentration showed a three-fold increase
after heparin administration. Although anecdotal, the
latter finding demonstrated that long-term treatment
does not cause HGF accumulation and heparin adminis-
tration is still effective in increasing HGF concentration
even after several months of treatment.
In conclusion, we show that heparin induces altera-
tions of the main HGF pharmacokinetic parameters in
the short term (as mentioned below) and that these
alterations also last after one month of daily treatmentFigure 3 Dose–response of HGF effects on apoptosis induction
by CDDP in vitro. The effect of HGF on SK-OV-3 ovarian cancer cells
is analysed by flow cytometry. SK-OV-3 cells are pretreated for 48 h
with HGF at the reported concentrations and then exposed to
20 μM CDDP for 48 h. A representative experiment out of five
performed is shown. The Y-axis shows the percentage of live cells, i.
e. cells that did not display either early or late apoptotic features.
These cells did not express phosphatidylserine on their surface
(Annexin V-FITC binding negative), did not display mitochondrial
depolarisation (they were not stained with tetramethylrhodamine
methyl ester, TMRM) and were not permeable to propidium iodide
(PI), as determined using multiparametric fluorescence activated cell
sorter analyses.
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parin might be suitable and effective when a clinical and
therapeutic use of HGF is anticipated.
We studied gynaecological patients with the intent of
exploiting the ability of HGF to sensitise ovarian cancer
cells to chemotherapeutic effects. Pre-clinical models
showed that HGF enhances the apoptotic effect of low
doses of PTX and CDDP on ovarian cancer cells [13-15].
Pre-clinical and in vitro models [13-15] showed that
both pre-treatment and continuous exposure of ovarian
cancer cells to HGF made them persistently susceptible
to drug-induced apoptosis. We demonstrate here that
HGF concentrations as low as those obtained after
nadroparin injection are effective in sensitising ovarian
cancer cells to chemotherapeutics. The combination of
these findings encourages further exploration of the pos-
sible role of LMWH as a chemo-potentiating agent in
ovarian cancer. The possibility of using LMWH in associ-
ation with chemotherapy (above all, low-doses CDDP and
PTX) could be beneficial in the treatment of epithelial
ovarian cancer because it could also take advantage of the
anti-neoplastic effects of LMWH shown in some studies
[23-26] and of its well known antithrombotic action.
The findings reported here are important also when
approaching tumour therapy from the perspective of
inhibiting HGF and MET, HGF is a Janus-faced mol-
ecule, which sensitizes ovarian cancer cells to che-
motherapeutics, but is alone able to trigger cancer cell
growth and invasiveness. Clinical trials are ongoing, also
in ECOC patients, with antibodies and small molecule
inhibitor targeting HGF or MET. HGF serum increase
after heparin treatment should be taken into account
also in this respect.
It has been definitively established that only cancer
cells with specific genetic alterations, namely either met
gene amplification or HGF autocrine loop maintain de-
pendence on the met gene activation for transformation,
i.e. remain met addicted. Therefore, only these cancer
cells could respond to met inhibition by small molecule
biochemical inhibitors or antibodies. In most instances,
HGF and MET axis elicits a number of signalling path-
ways leading to either cell survival and invasion or cell
death or differentiation.
In this study, we tested calcic nadroparin because it is
commonly used in our hospital for VTE prophylaxis.
Surprisingly, we found that nadroparin causes an eleva-
tion in HGF concentration that is higher than most
obtained with any LMWH reported in the literature. Sal-
bach PB. et al. [17], for instance, compared the effects of
un-fractionated heparin (UFH) and dalteparin on HGF
serum concentration in healthy male volunteers. They
obtained a similar time course of HGF increase but
lower HGF concentration. The main difference between
our studies lies in the gender of the patients. Seidel et al.[16] also reported a similarly lower increase of HGF
serum concentration following the administration of dal-
teparin and UFH to three groups of patients treated with
different schedules. Only Borawski J. et al. [18] reported
a higher increase in HGF concentration, but only after
enoxaparin administration in haemodialysed patients.
Therefore, it is possible that the striking HGF rise in our
patients was due to an amplified responsiveness of
patients undergoing surgery and anaesthesia. However,
the most likely explanation is that different effects
should be attributed to the different kinds of LMWH
used in the different studies, which have different
pharmacokinetics [27]. There are few studies in the lit-
erature comparing the pharmacodynamic profiles of the
different LMWHs with respect to HGF, such as that of
Rydzewska-Rosołowska et al., who reported that nadro-
parin, dalteparin and enoxaparin display similar capacity
of raising HGF serum concentration [28]. In conclusion,
our data show that nadroparin is a good candidate for a
possible use as an enhancer of chemotherapeutics be-
cause it has excellent bioavailability, a good safety profile
and a longer half-life than dalteparin.
The way by which heparin increases HGF serum con-
centration has yet to be completely clarified. A hypoth-
esis is that heparin could act by removing HGF from its
binding to cell surface and matrix proteoglycans [29]. In
this way, heparin could either increase HGF clearance
from the circulation or take it away from one of its
physiologic clearance mechanisms (the reabsorption by
the hepatocytes of the HGF-proteoglycans complex)
[17]. Heparin can increase the HGF concentration
through post-transcriptional regulation mechanisms in the
long term. Heparin does not only increase the serum HGF
concentration but also increases its activities [30,31] and
makes HGF more available in those tissues that need it
the most (for instance, ischemia harmed tissues) [17].
Conclusion
In conclusion, our study opens the possibility of using
LMWH to raise HGF serum concentration and take ad-
vantage of its biological activities. In particular, we hy-
pothesise that nadroparin could be used as a chemo-
potentiating agent in ECOC through its action on HGF
serum concentration.
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